Beijing’s 2010 Biopharmaceutical Sales Reach RMB 55.95 Billion
This article was originally published in PharmAsia News
Executive Summary
Beijing's biopharmaceutical sales reached RMB 55.95 billion in 2010, RMB 48.35 billion for product sales and RMB 7.6 billion from R&D services, according to the recent Beijing Biopharmaceutical Industry Development Project (G20 Project)'s 2010 conference
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.